Sanofi's Insulin Glargine Products Toujeo® and Lantus® Successfully Included in Category A of China's National Insulin Centralized Procurement

Shanghai, November 26, 2021 /PR Newswire/ -- The list of proposed winning results for the National Centralized Drug Procurement (Insulin Special Project) was announced today, featuring Sanofi's insulin product, Lantus.^®And Lantus^®Entered the A-list with the most extensive hospital channels, benefiting numerous patients in China.

Sanofi is the only multinational enterprise whose basal insulin entered the Category A list in this national drug procurement initiative in China. Sanofi is also the only multinational company with products that have successfully made it onto the lists of four batches of national drug procurement in China, which demonstrates Sanofi's profound commitment to Chinese patients with chronic diseases. With nearly 40 years of presence in China and supported by a robust innovative product pipeline, Sanofi continues to strive to serve Chinese patients and the healthcare ecosystem in China.

“The patient is me.ThemThe center of all work,ForMore patients will benefit from Sanofi's first-class insulin products, and we are deeply proud of this.ThemIt is a great honor toEnoughEffectively support the medical initiatives of the Chinese governmentTherapyHealthMeasures。Centralized Drug Procurementis a reMiscellaneousTheOverCheng, GovernmentComprehensivelyResearch to design a system that ensures optimal patient outcomesTreatment Efficacy Plan"，Dr. Hoenig, President of Sanofi Greater China, said."In the future, Sanofi will continue to accelerate the launch of new drugs and vaccines in China. We will also strengthen our R&D and production capabilities and promote digital innovation to improve patient outcomes."”

Sanofi's basal insulin product Lantus^®, Lantus^®And the fast-acting insulin Apidra^®Successfully entered the tentative list of winners for this national centralized drug procurement (insulin special project) in China.